 Victoria Pelak
Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vision Disorders | 13 | 2023 | 138 | 3.010 |
Why?
| | Alzheimer Disease | 7 | 2022 | 462 | 2.460 |
Why?
| | Neurodegenerative Diseases | 4 | 2022 | 90 | 2.260 |
Why?
| | Eye Movements | 3 | 2021 | 58 | 1.450 |
Why?
| | Cerebral Cortex | 6 | 2022 | 491 | 1.260 |
Why?
| | Atrophy | 4 | 2022 | 153 | 1.140 |
Why?
| | Eye Diseases | 2 | 2020 | 80 | 1.000 |
Why?
| | Lewy Body Disease | 2 | 2020 | 13 | 0.960 |
Why?
| | Cognitive Dysfunction | 3 | 2023 | 299 | 0.930 |
Why?
| | Tremor | 2 | 2021 | 45 | 0.880 |
Why?
| | Ocular Motility Disorders | 4 | 2018 | 27 | 0.860 |
Why?
| | Posterior Leukoencephalopathy Syndrome | 1 | 2021 | 12 | 0.850 |
Why?
| | Nervous System Diseases | 2 | 2020 | 256 | 0.850 |
Why?
| | Fragile X Syndrome | 1 | 2021 | 73 | 0.830 |
Why?
| | Visual Perception | 2 | 2022 | 151 | 0.830 |
Why?
| | Macular Degeneration | 1 | 2022 | 141 | 0.790 |
Why?
| | Mucolipidoses | 1 | 2019 | 7 | 0.760 |
Why?
| | Tomography, Optical Coherence | 4 | 2022 | 124 | 0.750 |
Why?
| | Reading | 1 | 2021 | 221 | 0.740 |
Why?
| | Visual Pathways | 3 | 2018 | 45 | 0.730 |
Why?
| | Dementia | 2 | 2011 | 196 | 0.700 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 365 | 0.670 |
Why?
| | Betacoronavirus | 2 | 2020 | 268 | 0.660 |
Why?
| | Coronavirus Infections | 2 | 2020 | 353 | 0.660 |
Why?
| | Ophthalmology | 1 | 2018 | 64 | 0.660 |
Why?
| | Visual Fields | 5 | 2022 | 79 | 0.640 |
Why?
| | Neurology | 1 | 2018 | 88 | 0.640 |
Why?
| | Androgens | 1 | 2016 | 161 | 0.550 |
Why?
| | Migraine Disorders | 1 | 2018 | 211 | 0.530 |
Why?
| | Aging | 3 | 2023 | 1690 | 0.510 |
Why?
| | Optic Neuropathy, Ischemic | 3 | 2012 | 28 | 0.500 |
Why?
| | Pandemics | 2 | 2020 | 1155 | 0.480 |
Why?
| | Testosterone | 1 | 2016 | 333 | 0.480 |
Why?
| | Humans | 44 | 2023 | 117633 | 0.410 |
Why?
| | Magnetic Resonance Imaging | 9 | 2019 | 3214 | 0.390 |
Why?
| | Cognition | 2 | 2023 | 1019 | 0.390 |
Why?
| | Optic Neuritis | 3 | 2020 | 33 | 0.380 |
Why?
| | Optic Nerve Diseases | 2 | 2009 | 31 | 0.380 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2020 | 38 | 0.370 |
Why?
| | Vision, Low | 1 | 2009 | 13 | 0.370 |
Why?
| | Inflammation | 1 | 2020 | 2538 | 0.370 |
Why?
| | Optic Nerve | 1 | 2009 | 66 | 0.360 |
Why?
| | Giant Cell Arteritis | 3 | 2020 | 44 | 0.330 |
Why?
| | Congresses as Topic | 2 | 2019 | 204 | 0.320 |
Why?
| | Brain Diseases | 2 | 2017 | 155 | 0.310 |
Why?
| | Visual Acuity | 6 | 2022 | 263 | 0.300 |
Why?
| | Cataract Extraction | 1 | 2006 | 63 | 0.290 |
Why?
| | Pseudotumor Cerebri | 2 | 2016 | 22 | 0.260 |
Why?
| | Nerve Net | 2 | 2022 | 258 | 0.260 |
Why?
| | Male | 22 | 2022 | 60403 | 0.250 |
Why?
| | Cognition Disorders | 2 | 2023 | 580 | 0.240 |
Why?
| | Cognitive Aging | 1 | 2023 | 11 | 0.240 |
Why?
| | Aged | 10 | 2023 | 20249 | 0.230 |
Why?
| | Lewy Bodies | 1 | 2022 | 5 | 0.230 |
Why?
| | Immunosuppressive Agents | 4 | 2020 | 690 | 0.230 |
Why?
| | Unconsciousness | 1 | 2022 | 19 | 0.230 |
Why?
| | Amnesia | 2 | 2012 | 36 | 0.220 |
Why?
| | Ataxia | 1 | 2021 | 41 | 0.220 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 90 | 0.210 |
Why?
| | Trochlear Nerve Diseases | 1 | 2001 | 6 | 0.210 |
Why?
| | Middle Aged | 16 | 2022 | 28659 | 0.210 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2021 | 62 | 0.210 |
Why?
| | Abducens Nerve Diseases | 1 | 2001 | 10 | 0.210 |
Why?
| | Neuropsychological Tests | 3 | 2022 | 1115 | 0.210 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2001 | 13 | 0.210 |
Why?
| | Stents | 2 | 2016 | 423 | 0.200 |
Why?
| | Myasthenia Gravis | 1 | 2020 | 18 | 0.200 |
Why?
| | Autonomic Fibers, Preganglionic | 1 | 1999 | 4 | 0.190 |
Why?
| | Siderosis | 1 | 1999 | 3 | 0.190 |
Why?
| | Pupil | 1 | 1999 | 14 | 0.190 |
Why?
| | Eye Movement Measurements | 1 | 2019 | 12 | 0.190 |
Why?
| | Immunomodulation | 1 | 2020 | 87 | 0.190 |
Why?
| | Steroids | 1 | 2020 | 143 | 0.190 |
Why?
| | Female | 20 | 2022 | 63247 | 0.190 |
Why?
| | West Nile Fever | 1 | 2020 | 53 | 0.190 |
Why?
| | Brain Stem | 1 | 2000 | 110 | 0.190 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2019 | 36 | 0.190 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 153 | 0.190 |
Why?
| | Hearing Loss | 1 | 2023 | 189 | 0.180 |
Why?
| | San Francisco | 1 | 2018 | 51 | 0.180 |
Why?
| | Frontotemporal Dementia | 1 | 2019 | 28 | 0.180 |
Why?
| | Facial Recognition | 1 | 2019 | 30 | 0.180 |
Why?
| | Immune System | 1 | 2020 | 194 | 0.180 |
Why?
| | Facial Expression | 1 | 2019 | 77 | 0.170 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2018 | 30 | 0.170 |
Why?
| | Vestibule, Labyrinth | 1 | 2018 | 49 | 0.170 |
Why?
| | Epilepsy, Temporal Lobe | 1 | 2017 | 22 | 0.160 |
Why?
| | Brain | 5 | 2022 | 2699 | 0.160 |
Why?
| | Transverse Sinuses | 1 | 2016 | 7 | 0.160 |
Why?
| | Diffusion Tensor Imaging | 1 | 2017 | 74 | 0.150 |
Why?
| | Critical Care | 1 | 2021 | 519 | 0.150 |
Why?
| | Papilledema | 2 | 2018 | 38 | 0.150 |
Why?
| | Immunotherapy | 1 | 2020 | 477 | 0.150 |
Why?
| | Laser Therapy | 1 | 2017 | 97 | 0.140 |
Why?
| | Adult | 13 | 2022 | 32118 | 0.140 |
Why?
| | Universities | 1 | 2018 | 354 | 0.140 |
Why?
| | Postoperative Complications | 1 | 2006 | 2113 | 0.140 |
Why?
| | Case-Control Studies | 2 | 2021 | 3269 | 0.140 |
Why?
| | Amygdala | 1 | 2017 | 190 | 0.140 |
Why?
| | Brain Mapping | 3 | 2022 | 593 | 0.130 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 999 | 0.130 |
Why?
| | Parkinson Disease | 1 | 2018 | 353 | 0.130 |
Why?
| | Multiple Sclerosis | 3 | 2020 | 363 | 0.120 |
Why?
| | Biomedical Research | 1 | 2019 | 598 | 0.120 |
Why?
| | Optic Disk Drusen | 1 | 2012 | 5 | 0.110 |
Why?
| | Autoantibodies | 2 | 2018 | 1292 | 0.110 |
Why?
| | Retrospective Studies | 6 | 2020 | 12331 | 0.110 |
Why?
| | Visual Field Tests | 1 | 2011 | 14 | 0.110 |
Why?
| | Cranial Sinuses | 1 | 2011 | 9 | 0.110 |
Why?
| | Hemianopsia | 1 | 2011 | 8 | 0.110 |
Why?
| | Optic Disk | 2 | 2009 | 37 | 0.110 |
Why?
| | Memory, Episodic | 1 | 2012 | 39 | 0.110 |
Why?
| | Hippocampus | 1 | 2017 | 811 | 0.110 |
Why?
| | Hemodynamics | 1 | 2016 | 1085 | 0.110 |
Why?
| | Quality of Life | 1 | 2022 | 2354 | 0.100 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 148 | 0.100 |
Why?
| | Diagnosis, Differential | 3 | 2009 | 1405 | 0.100 |
Why?
| | Biomarkers | 1 | 2020 | 3574 | 0.090 |
Why?
| | Nervous System Malformations | 1 | 2009 | 30 | 0.090 |
Why?
| | Stiff-Person Syndrome | 1 | 2008 | 6 | 0.090 |
Why?
| | Hypokinesia | 1 | 2008 | 8 | 0.090 |
Why?
| | Age of Onset | 2 | 2020 | 470 | 0.080 |
Why?
| | Arteritis | 1 | 2006 | 28 | 0.080 |
Why?
| | Rest | 2 | 2022 | 135 | 0.080 |
Why?
| | Spinal Nerve Roots | 1 | 2005 | 32 | 0.070 |
Why?
| | Cranial Nerve Diseases | 1 | 2005 | 45 | 0.070 |
Why?
| | Blindness, Cortical | 1 | 2003 | 5 | 0.060 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2005 | 136 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 1971 | 0.060 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2003 | 84 | 0.060 |
Why?
| | Adolescent | 6 | 2020 | 18902 | 0.060 |
Why?
| | Pulvinar | 1 | 2022 | 6 | 0.060 |
Why?
| | Young Adult | 4 | 2022 | 11077 | 0.060 |
Why?
| | Pre-Eclampsia | 1 | 2003 | 151 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2017 | 4911 | 0.050 |
Why?
| | Diplopia | 1 | 2001 | 13 | 0.050 |
Why?
| | Connectome | 1 | 2022 | 54 | 0.050 |
Why?
| | Strabismus | 1 | 2001 | 24 | 0.050 |
Why?
| | Functional Laterality | 1 | 2022 | 207 | 0.050 |
Why?
| | Treatment Failure | 2 | 2016 | 340 | 0.050 |
Why?
| | Animals | 3 | 2020 | 34350 | 0.050 |
Why?
| | Vision Tests | 1 | 2000 | 14 | 0.050 |
Why?
| | Vision, Ocular | 1 | 2000 | 28 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2020 | 86 | 0.050 |
Why?
| | Temporal Lobe | 2 | 2012 | 89 | 0.050 |
Why?
| | Demyelinating Diseases | 1 | 2020 | 79 | 0.050 |
Why?
| | New Orleans | 1 | 2019 | 9 | 0.050 |
Why?
| | Eye Pain | 1 | 2018 | 7 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2018 | 59 | 0.040 |
Why?
| | Encephalitis | 1 | 2020 | 130 | 0.040 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 241 | 0.040 |
Why?
| | Recurrence | 1 | 2020 | 1009 | 0.040 |
Why?
| | Focus Groups | 1 | 2018 | 376 | 0.040 |
Why?
| | Transfection | 1 | 2018 | 910 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2018 | 656 | 0.040 |
Why?
| | Child, Preschool | 2 | 2020 | 9714 | 0.030 |
Why?
| | Hospital Mortality | 1 | 1999 | 853 | 0.030 |
Why?
| | Patient Participation | 1 | 2018 | 362 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2018 | 1132 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2018 | 786 | 0.030 |
Why?
| | Emotions | 1 | 2019 | 473 | 0.030 |
Why?
| | Qualitative Research | 1 | 2018 | 856 | 0.030 |
Why?
| | Child | 3 | 2020 | 18649 | 0.030 |
Why?
| | Color Vision Defects | 1 | 2012 | 6 | 0.030 |
Why?
| | Spinal Puncture | 1 | 2012 | 27 | 0.030 |
Why?
| | Disease Management | 1 | 2016 | 603 | 0.030 |
Why?
| | Phlebography | 1 | 2011 | 37 | 0.030 |
Why?
| | Colorado | 1 | 2022 | 4401 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 2011 | 91 | 0.030 |
Why?
| | Lymphokines | 1 | 1991 | 125 | 0.030 |
Why?
| | Stroke | 1 | 1999 | 992 | 0.030 |
Why?
| | Hospitalization | 1 | 1999 | 1774 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 2875 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4842 | 0.020 |
Why?
| | Autoradiography | 1 | 1989 | 81 | 0.020 |
Why?
| | Supranuclear Palsy, Progressive | 1 | 2008 | 6 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 1991 | 312 | 0.020 |
Why?
| | Macaca mulatta | 1 | 1989 | 129 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 1991 | 375 | 0.020 |
Why?
| | Blindness | 1 | 2008 | 34 | 0.020 |
Why?
| | Oculomotor Muscles | 1 | 2008 | 39 | 0.020 |
Why?
| | Brain Chemistry | 1 | 1989 | 148 | 0.020 |
Why?
| | Saccades | 1 | 2008 | 55 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1451 | 0.020 |
Why?
| | Withholding Treatment | 1 | 2008 | 72 | 0.020 |
Why?
| | Glutamate Decarboxylase | 1 | 2008 | 165 | 0.020 |
Why?
| | Frontal Lobe | 1 | 1989 | 164 | 0.020 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2008 | 166 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2008 | 128 | 0.020 |
Why?
| | Neural Inhibition | 1 | 2008 | 171 | 0.020 |
Why?
| | Pilot Projects | 1 | 2012 | 1441 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1991 | 616 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 1991 | 1078 | 0.020 |
Why?
| | Electromyography | 1 | 2008 | 336 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1897 | 0.020 |
Why?
| | Cohort Studies | 1 | 2016 | 5112 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2011 | 9353 | 0.020 |
Why?
| | Cranial Nerves | 1 | 2005 | 12 | 0.020 |
Why?
| | Sural Nerve | 1 | 2005 | 20 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2005 | 48 | 0.020 |
Why?
| | Hypertrophy | 1 | 2005 | 122 | 0.020 |
Why?
| | Graves Disease | 1 | 2005 | 33 | 0.020 |
Why?
| | Amino Acids | 1 | 1989 | 437 | 0.020 |
Why?
| | Myelin Sheath | 1 | 2005 | 144 | 0.020 |
Why?
| | Axons | 1 | 2005 | 180 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2011 | 2948 | 0.020 |
Why?
| | Mice | 1 | 2020 | 15537 | 0.020 |
Why?
| | Disease Progression | 1 | 2008 | 2541 | 0.010 |
Why?
| | Contrast Sensitivity | 1 | 2000 | 13 | 0.010 |
Why?
| | Observer Variation | 1 | 2000 | 326 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2008 | 1539 | 0.010 |
Why?
| | Reference Values | 1 | 2000 | 835 | 0.010 |
Why?
| | Walking | 1 | 2000 | 434 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2462 | 0.010 |
Why?
| | Pregnancy | 1 | 2003 | 5554 | 0.010 |
Why?
| | Age Factors | 1 | 1999 | 3223 | 0.010 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 88 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1991 | 195 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 1991 | 84 | 0.010 |
Why?
| | Receptors, IgG | 1 | 1991 | 72 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 1991 | 85 | 0.010 |
Why?
| | CD3 Complex | 1 | 1991 | 91 | 0.010 |
Why?
| | Receptors, Fc | 1 | 1991 | 44 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 1991 | 288 | 0.010 |
Why?
| | Base Sequence | 1 | 1991 | 2171 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1991 | 2898 | 0.000 |
Why?
| | Gene Expression | 1 | 1991 | 1520 | 0.000 |
Why?
| | RNA | 1 | 1991 | 788 | 0.000 |
Why?
|
|
Pelak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|